Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide Phase 2 Obesity Trial
NCT00422058Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2007
- Primary completion
- Sep 2007
- Modality
- Peptides
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of liraglutide in obesity (6 arms), sponsored by Novo Nordisk. Primary endpoint: Mean Change From Baseline in Body Weight at 20 weeks. Started Jan 2007; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00422058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422058.